Xinhua Deng – Trademark Portfolio

Entity Type: 01

Xinhua Deng holds 3 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 2 filings in this category. The portfolio also extends into Class 10 (Medical Apparatus) across 2 Nice Classification classes. Currently, 3 trademarks are registered. Notable registered marks include DIYTAR, TUNTUN, and WISULUK. The owner is based in Leiyang City, Hunan.

Group 15, Tianxin Village, Nanyang Town,

Leiyang City, Hunan 421800 , CN

3 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

DIYTAR
DIYTAR
Registered 2025
TUNTUN
TUNTUN
Registered 2025
WISULUK
WISULUK
Registered 2025

Trademark Classifications

Xinhua Deng's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (2 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

10
Medical Apparatus (1 filing)

Surgical, medical, dental and veterinary apparatus and instruments

Frequently Asked Questions

How many trademarks does Xinhua Deng have?

Xinhua Deng has 3 U.S. trademarks filed with the USPTO. Of these, 3 registered.

What trademark classes does Xinhua Deng file in?

Xinhua Deng files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are Xinhua Deng's most well-known trademarks?

Xinhua Deng's registered trademark portfolio includes well-known marks such as DIYTAR, TUNTUN, and WISULUK. These are among 3 currently registered trademarks in the portfolio.

What is Xinhua Deng's trademark registration success rate?

Xinhua Deng has a 100% trademark registration rate, with 3 out of 3 resolved applications resulting in successful registration. Currently, 0 applications are pending review.